{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG002","value":"19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"ADA-negative at baseline, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"ADA-positive at post-baseline, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG002","value":"19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"ADA-negative at baseline, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"ADA-positive at post-baseline, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG002","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"ADA-negative at baseline, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"ADA-positive at post-baseline, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG002","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"ADA-negative at baseline, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"ADA-positive at post-baseline, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"ADA-negative at baseline, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"ADA-positive at post-baseline, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Validated immunoassays were used for screening and confirmation of the presence of anti-LAG525 antibodies (ADA, anti-drug antibodies) in serum. Number of participants with ADA in each category is reported in this record.","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 and who had a determinant baseline immunogenicity (IG) sample and at least one determinant post-baseline IG sample. A determinant IG sample is neither ADA-inconclusive nor unevaluable.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).","title":"Phase 2: Number of Participants With Anti-LAG525 Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}